The purpose of this study is to learn if a study drug called Guanfacine is helpful in
treating hyperactivity and impulsiveness in children with PDD. Guanfacine is widely
used for the treatment of hyperactivity and impulsiveness in this population, but has not
been carefully studied. It is approved by the FDA for the treatment of hypertension, but a
long-acting formula has recently been approved to treat Attention-Deficit/Hyperactivity
Disorder in children. This study will also determine if adding methylphenidate (MPH) on
top of guanfacine will improve hyperactive and impulsive symptoms in children who are
not responding positively to guanfacine alone. MPH is FDA approved for the treatment
of these symptoms in children.
Youth diagnosed with an Autism Spectrum Disorder between the ages of 5 and 14 years with high levels of Hyperactive or Impulsive Behavior.
Participants will recieve Guanfacine or placebo (some children may also receive methylphenidate). Youth selected for the study will participate in questionnaires, interviews, psychological and laboratory testing.
Eligible youth will receive $25 for each study visit.
For more information, please call UCLA at (310) 794-2215.
Originally created: 5 Mar 2012 Current author: Dr. Candace J. Wi...
Jane & Terry Semel Institute for Neuroscience & Human Behavior
760 Westwood Plaza
Los Angeles, CA 90095
UCLA Health System School of Medicine
(c) UC Regents 2011 Privacy Notice
Help Sitemap A-Z index